Sessions are scheduled in local time (CEST)
Browsing Over 485 Presentations
Sort By
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Assessing risk of recurrence in HR-positive, HER2-negative early breast cancer (ID 499)
Lecture Time
12:30 - 12:30
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
- All Speakers (na, Switzerland)
Authors
- All Speakers (na, Switzerland)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?
Reacting to a dynamic disease (ID 67)
Lecture Time
11:35 - 11:45
Session Name
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
- Komal Jhaveri (New York, NY, United States of America)
Authors
- Komal Jhaveri (New York, NY, United States of America)
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer
First-line treatment in HR+/HER2- ABC: Patient cases (ID 13)
Lecture Time
11:35 - 12:00
Room
Frankfurt Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
- Sherko Kuemmel (Essen, Germany)
Authors
- Sherko Kuemmel (Essen, Germany)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Impact of oral targeted adjuvant therapies in patients with HR-positive, HER2-negative early breast cancer (ID 500)
Lecture Time
12:30 - 12:30
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
- All Speakers (na, Switzerland)
Authors
- All Speakers (na, Switzerland)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?
Moving ahead of a dynamic disease (ID 68)
Lecture Time
11:45 - 11:55
Session Name
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
- François Clément Bidard (Paris, CE, France)
Authors
- François Clément Bidard (Paris, CE, France)
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer
Sequencing following progression after first-line CDK4/6i: Patient cases (ID 14)
Lecture Time
12:00 - 12:20
Room
Frankfurt Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
- Michelino De Laurentiis (Napoli, Italy)
Authors
- Michelino De Laurentiis (Napoli, Italy)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Optimizing adherence and persistence with oral targeted adjuvant therapies in HR-positive, HER2-negative early breast cancer (ID 501)
Lecture Time
12:30 - 12:30
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
- All Speakers (na, Switzerland)
Authors
- All Speakers (na, Switzerland)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?
Gaining momentum with new modalities (ID 69)
Lecture Time
11:55 - 12:05
Session Name
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
- Javier Cortes (Madrid and Barcelona, Spain)
Authors
- Javier Cortes (Madrid and Barcelona, Spain)
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer
Closing and key takeaways (ID 15)
Lecture Time
12:20 - 12:25
Room
Frankfurt Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
- To be Announced (Barcelona, Spain)
Authors
- To be Announced (Barcelona, Spain)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Shared decision-making in HR-positive, HER2-negative early breast cancer: Enhancing patient-provider communication (ID 502)
Lecture Time
12:30 - 12:30
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
- All Speakers (na, Switzerland)
Authors
- All Speakers (na, Switzerland)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?
Q&A / discussion (ID 70)
Lecture Time
12:05 - 12:30
Session Name
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
- To be Announced (Barcelona, Spain)
Authors
- To be Announced (Barcelona, Spain)
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer
Live Q&A (ID 16)
Lecture Time
12:25 - 12:30
Room
Frankfurt Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
- To be Announced (Barcelona, Spain)
Authors
- To be Announced (Barcelona, Spain)